GlycoMimetics Inc (NASDAQ:GLYC)
| 8.22 Data as of Jul 22 |  +0.05 / +0.61%Today’s Change | 6.02 Today|||52-Week Range 18.99 | -- Year-to-Date |
Latest GLYC News | Press Releases
No recent news for GlycoMimetics Inc.
Today’s Trading
| Previous close | 8.17 |
| Today’s open | 8.21 |
| Day’s range | -- - -- |
| Volume | 48,908 |
| Average volume (3 months) | 138,282 |
| Market cap | $153.5M |
| Dividend yield | -- |
Data as of 07/22/2014
Growth & Valuation
| Earnings growth (last year) | -272.73% |
| Earnings growth (this year) | +101.24% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -73.83% |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | 52.84 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CPRXCatalyst Pharmaceuti... | +0.01 | +0.45% |
| SRNESorrento Therapeutic... | +0.34 | +6.67% |
| STMLStemline Therapeutic... | +0.29 | +2.66% |
| MEIPMEI Pharma Inc | +0.30 | +4.53% |
Data as of 07/22/2014
Financials
| Next reporting date | September 3, 2014 |
| EPS forecast (this quarter) | $0.25 |
| Annual revenue (last year) | $4.0M |
| Annual profit (last year) | -$10.6M |
| Net profit margin | -265.63% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Rachel K. King |
Chief Financial Officer & Head-Media Relations Brian M. Hahn |
Corporate headquarters Gaithersburg, Maryland |
Forecasts
.
